Advertisement

Topics

Glycine vs Placebo for the Schizophrenia Prodrome

2014-08-27 03:46:09 | BioPortfolio

Summary

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Schizophrenia Prodrome

Intervention

Glycine, Placebo

Location

PRIME Clinic
New Haven
Connecticut
United States
06519

Status

Completed

Source

Yale University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:46:09-0400

Clinical Trials [1098 Associated Clinical Trials listed on BioPortfolio]

Glycine Treatment of Prodromal Symptoms

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairment...

Ethyl-EPA Treatment of Prodromal Patients

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia

The purpose of this study is to evaluate the effect of a dietary supplement on the concentration of a small protein called glycine that is found in the brain in people with schizophrenia. ...

Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia

Prodrome based early intervention with an antipsychotic drug vs. benzodiazepine was applied in patients with first episode schizophrenia after one year neuroleptic maintenance treatment. T...

PubMed Articles [2050 Associated PubMed Articles listed on BioPortfolio]

Prodrome and Non-Prodrome Phenotypes of Bladder Pain Syndrome/Interstitial Cystitis.

To test the hypothesis that risk factors for BPS/IC in women differ between those with and without the BPS/IC prodrome.

Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study).

Sarcosine, glycine transporter inhibitor, increases glycine levels around NMDA receptor, improving primary negative symptoms of schizophrenia. The aim of our study was to find a potential relationship...

Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial.

Schizophrenia presents with a broad range of negative, positive, and cognitive symptoms, and comprehensive treatment is still a challenge. Sodium nitroprusside (SNP) has been reported to rapidly reduc...

Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.

Although currently approved antipsychotics exert efficacy on positive symptoms of schizophrenia, treatments for negative symptoms remain a major unmet need. Post hoc analyses were used to investigate ...

Five years before multiple sclerosis onset: Phenotyping the prodrome.

The multiple sclerosis (MS) prodrome is poorly characterized.

Medical and Biotech [MESH] Definitions

A PYRIDOXAL PHOSPHATE dependent enzyme that catalyzes the decarboxylation of GLYCINE with the transfer of an aminomethyl group to the LIPOIC ACID moiety of the GLYCINE DECARBOXYLASE COMPLEX H-PROTEIN. Defects in P-protein are the cause of non-ketotic hyperglycinemia. It is one of four subunits of the glycine decarboxylase complex.

A family of sodium chloride-dependent neurotransmitter symporters that transport the amino acid GLYCINE. They differ from GLYCINE RECEPTORS, which signal cellular responses to GLYCINE. They are located primarily on the PLASMA MEMBRANE of NEURONS; GLIAL CELLS; EPITHELIAL CELLS; and RED BLOOD CELLS where they remove inhibitory neurotransmitter glycine from the EXTRACELLULAR SPACE.

Cell surface receptors that bind glycine with high affinity and trigger intracellular changes which influence the behavior of cells. Glycine receptors in the central nervous system have an intrinsic chloride channel and are usually inhibitory.

An oxidoreductase that catalyzes the oxidative DEAMINATION of GLYCINE to glyoxylate and AMMONIA in the presence of NAD. In BACTERIA lacking transaminating pathways the enzyme can act in the reverse direction to synthesize glycine from glyoxylate and ammonia and NADH.

A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.

More From BioPortfolio on "Glycine vs Placebo for the Schizophrenia Prodrome"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...


Searches Linking to this Trial